Optimization of the Dosage of Flucytosine in Combination with Amphotericin B for Disseminated Candidiasis: a Pharmacodynamic Rationale for Reduced Dosing
- 1 October 2007
- journal article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 51 (10), 3760-3762
- https://doi.org/10.1128/aac.00488-07
Abstract
Amphotericin B and flucytosine (5FC) have an additive effect when used for disseminated candidiasis. Here, we bridge the results of an experimental pharmacodynamic study to humans and demonstrate that a 5FC dosage of 25 mg/kg of body weight/day in four divided doses in combination with amphotericin B produces near-maximal effect.Keywords
This publication has 12 references indexed in Scilit:
- Pathogenesis ofAspergillus fumigatusand the Kinetics of Galactomannan in an In Vitro Model of Early Invasive Pulmonary Aspergillosis: Implications for Antifungal TherapyThe Journal of Infectious Diseases, 2007
- Derivation of an In Vivo Drug Exposure Breakpoint for Flucytosine against Candida albicans and Impact of the MIC, Growth Rate, and Resistance Genotype on the Antifungal EffectAntimicrobial Agents and Chemotherapy, 2006
- Pharmacodynamic Activity of Amphotericin B Deoxycholate Is Associated with Peak Plasma Concentrations in a Neutropenic Murine Model of Invasive Pulmonary AspergillosisAntimicrobial Agents and Chemotherapy, 2006
- Surface Response Modeling to Examine the Combination of Amphotericin B Deoxycholate and 5‐Fluorocytosine for Treatment of Invasive CandidiasisThe Journal of Infectious Diseases, 2005
- Application of an In Vitro Infection Model and Simulation for Reevaluation of Fluoroquinolone Breakpoints for Salmonella enterica Serotype TyphiAntimicrobial Agents and Chemotherapy, 2005
- Model appropriateness and population pharmacokinetic modeling.2003
- In Vitro Activities of 5-Fluorocytosine against 8,803 Clinical Isolates of Candida spp.: Global Assessment of Primary Resistance Using National Committee for Clinical Laboratory Standards Susceptibility Testing MethodsAntimicrobial Agents and Chemotherapy, 2002
- Pharmacodynamics of Amphotericin B in a Neutropenic-Mouse Disseminated-Candidiasis ModelAntimicrobial Agents and Chemotherapy, 2001
- In Vivo Characterization of the Pharmacodynamics of Flucytosine in a Neutropenic Murine Disseminated Candidiasis ModelAntimicrobial Agents and Chemotherapy, 2000
- Evolving Role of Flucytosine in Immunocompromised Patients: New Insights into Safety, Pharmacokinetics, and Antifungal TherapyClinical Infectious Diseases, 1992